Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Poseida Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PSTX
Nasdaq
8731
https://poseida.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Poseida Therapeutics Inc
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
- Mar 25th, 2024 8:05 pm
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Mar 19th, 2024 8:05 pm
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
- Mar 13th, 2024 8:05 pm
US$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These Results
- Mar 10th, 2024 1:55 pm
Poseida Therapeutics Full Year 2023 Earnings: Beats Expectations
- Mar 9th, 2024 1:21 pm
Poseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 8th, 2024 3:45 am
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
- Mar 7th, 2024 11:55 pm
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
- Mar 7th, 2024 9:05 pm
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Mar 4th, 2024 9:05 pm
Institutional investors own a significant stake of 41% in Poseida Therapeutics, Inc. (NASDAQ:PSTX)
- Feb 27th, 2024 10:45 am
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones
- Jan 4th, 2024 1:00 pm
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
- Dec 10th, 2023 5:00 pm
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
- Nov 17th, 2023 6:08 pm
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023
- Nov 9th, 2023 9:05 pm
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
- Nov 7th, 2023 1:00 pm
Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Nov 2nd, 2023 2:00 pm
Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition
- Nov 2nd, 2023 1:01 pm
All You Need to Know About Poseida Therapeutics, Inc. (PSTX) Rating Upgrade to Buy
- Oct 16th, 2023 4:00 pm
Poseida Therapeutics Announces Leadership Transition
- Oct 9th, 2023 8:30 pm
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
- Oct 3rd, 2023 9:00 pm
Scroll